Novo Nordisk's Road Back Runs Through the Factory Floor, Not the Lab

Novo Nordisk stock is down 23% in 2026 as an FDA review delay pushes its hemophilia A launch to 2027 and Danish regulators cite unlawful ads.

Novo Nordisk shares are nursing a 23% year-to-date decline, and the reasons have less to do with the science of weight loss than with the unglamorous mechanics of making and marketing medicine. The Danish drugmaker closed Tuesday at EUR 33.97, having ended Monday at EUR 34.04 — a level that leaves it 38% below its 52-week high and uncomfortably close to recent lows.

What has emerged from the past several weeks is a company whose pipeline ambitions are running ahead of its ability to satisfy regulators on two separate fronts: manufacturing standards and marketing conduct.

A Hemophilia Launch Slips to 2027

The clearest example sits in Novo's hemophilia A program. The FDA has extended its review of Denecimig, citing remediation work needed at a production site. The agency set no new decision date, though it raised no concerns about the submitted efficacy or safety data.

Novo has told investors the delay will not dent its 2026 financial guidance. Even so, the US commercial launch — contingent on approval — has been pushed to the first half of 2027. The episode carries a broader lesson for the sector: laboratory breakthroughs only convert into revenue when manufacturing sites clear the bar set by watchdogs.

Buying a Seat at the Oral Table

While the FDA review drags on, Novo has moved to broaden its metabolic franchise through licensing. The company secured exclusive rights outside mainland China, Hong Kong, Macao and Taiwan to HRS-1596, an oral dual GLP-1/GIP receptor agonist from Jiangsu Hengrui Pharmaceuticals that is ready to enter Phase 1 trials.

The deal carries a USD 300 million upfront payment and could reach USD 2.6 billion including milestones, plus tiered royalties on future sales. If the transaction closes as planned in the fourth quarter of 2026, it would gradually reduce Novo's reliance on injectable formats — a strategic priority, since oral options are widely viewed as the key to reaching broader patient populations in cardiometabolic care.

Fresh Data Hint at Broader Benefits

There are also signs that Novo's existing semaglutide portfolio has more room to run. An exploratory post-hoc subgroup analysis of the STEP-UP trial found that among 26 participants with baseline liver fat above 5%, 23 dropped below that threshold after 72 weeks of treatment. The analysis pooled 7.2 mg and 2.4 mg doses of injectable Wegovy.

Separately, CagriSema data presented at the EASD conference — roughly a week ago, since when the stock has added 1.6% — pointed to benefits beyond weight loss, including reduced visceral fat and stable bone markers alongside a dampening of persistent hunger.

Copenhagen Turns Up the Heat

The regulatory pressure is not confined to Washington. Danish media reports indicate Novo has breached legal provisions four times in 2026, three of them involving unlawful direct-to-consumer advertising of weight-loss drugs on LinkedIn. Danish rules prohibit such promotion of prescription medicines outright.

The pharma industry's Danish ethics committee had already fined the company DKK 45,000 plus VAT on 28 September over a joint patient-support program for Wegovy run with service provider Falck, and ordered the arrangement halted in its existing form. Novo subsequently ended the partnership, according to the reports, while making clear it disagreed with the committee's ruling.

Analysts Trim Targets, Keep Their Splits

Against that backdrop, sell-side views remain divided. Danske Bank cut its price target to DKK 345 from DKK 365 on Wednesday while retaining a Buy rating. Deutsche Bank stayed at Sell and lowered its target to DKK 225 from DKK 245, citing what it deemed subdued EASD data.

The bear case rests on the risk that the FDA's Denecimig review stays open beyond year-end without a timeline, potentially derailing the first-half 2027 launch. Licensed assets such as HRS-1596 carry their own development risk: the molecule may be Phase 1-ready, but human efficacy and tolerability data in a Western regulatory setting are still at square one, and a failure in early trials would write off the upfront payment with no operating return.

What to Watch

The next hard catalyst is the HRS-1596 licensing close targeted for the fourth quarter of 2026. Investors will also track how quickly Novo can complete remediation at the Denecimig manufacturing site to protect the 2027 launch window.

Meanwhile, the company continues a share buyback worth up to DKK 15 billion, running through February 2027, steadily shrinking the free float. As long as the stock holds its recent lows, the prospect of stabilization survives — but another round of approval or production setbacks would push the old 52-week peak further out of reach.